Agonist of aryl hydrocarbon receptor for use in cancer combination therapy
AssigneesInstitut Curie, Inserm (Institut National De La Sante Et De La Recherche Medicale)
InventorsSebastian Amigorena, Elodie Segura
Life of this patent
Estimating the term…
Abstract
The present invention relates to an AhR agonist for use in combination with at least one immune checkpoint modulator in the treatment of cancer. The present invention also encompasses product containing an AhR agonist and at least one immune checkpoint modulator as defined in any one of the preceding, claims, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.
Claims15
An AhR agonist for use in combination with at least one immune checkpoint modulator in the treatment of cancer.
Method for treating a patient suffering from cancer, wherein said method comprises the combined administration of an effective amount of one or more AHR agonist and an effective amount of at least one immune checkpoint modulator.
Dependencies are inferred from the claim text.